Status:
UNKNOWN
Use of Superparamagnetic Iron Oxide (SPIO) in Sentinel Lymph Node Detection for Breast Cancer
Lead Sponsor:
The University of Hong Kong
Conditions:
Breast Cancer
Sentinel Lymph Node
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Sentinel lymph node biopsy is mandatory during breast cancer operation for disease staging and treatment. The localization of sentinel lymph node is by the injection of radioisotope and blue dye, whic...
Detailed Description
Sentinel lymph node biopsy has replaced axillary dissection as the standard of care in clinically node negative breast cancer. Lymphatic mapping with radioisotope and blue dye were most studied tracer...
Eligibility Criteria
Inclusion
- All patients with clinical T1-3N0 invasive ductal carcinoma or invasive lobular carcinoma planned for breast conservative surgery or mastectomy, with sentinel lymph node biopsy
- Patients planned for upfront operation or neoadjuvant chemotherapy are allowed
Exclusion
- Patients with hypersensitivity to dextran compounds, iron or blue dye
- Patients with iron overload disease
- Pregnant or lactating patients
- Patients with pacemaker or other implantable metallic devices in chest wall or prosthesis in shoulder
- Mentally incompetent patients
Key Trial Info
Start Date :
July 24 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2024
Estimated Enrollment :
282 Patients enrolled
Trial Details
Trial ID
NCT05288686
Start Date
July 24 2018
End Date
June 30 2024
Last Update
May 10 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Hong Kong
Hong Kong, Hong Kong